The court has said that Cephalon‘s US Patent number 6,264,981is valid and also found that Watson Pharma’s proposed generic version of Fentora (fentanyl buccal tablet) infringes that patent.
The Court also denied Watson Pharma‘s motion to vacate a previously entered injunction preventing Watson from marketing its product.
Cephalon General Counsel executive vice president Jerry Pappert said they are pleased with the court’s ruling upholding the validity of their patent, as well as its finding that Watson’s product infringes that patent.